{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010921","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.699348+00:00","generated_at":"2026-06-04T09:02:56.135188+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Matinas BioPharma reports complete clinical response in 3 fusarium patients with oral MAT2203","bullets":["Three patients with azole-resistant invasive fusarium infection achieved complete clinical response after oral MAT2203 treatment.","Two of these patients had not yet achieved complete resolution at the time of the prior 19-patient update.","Patients could not tolerate IV amphotericin B due to nephrotoxicity; oral MAT2203 resolved infections over 2 weeks to 6 months.","Results bolster confidence for upcoming Phase 3 ORALTO trial in invasive aspergillosis with limited treatment options.","MAT2203 is not yet licensed or approved anywhere globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010921","json":"https://secwatch.observer/filing/0001493152-24-010921.json","markdown":"https://secwatch.observer/filing/0001493152-24-010921.md","text":"https://secwatch.observer/filing/0001493152-24-010921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224010921/0001493152-24-010921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224010921/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:02:56.135188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}